[HTML][HTML] Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
…, RAS Hoek, MM van der Eerden, DA Hesselink… - Nature …, 2021 - nature.com
Key questions in COVID-19 are the duration and determinants of infectious virus shedding.
Here, we report that infectious virus shedding is detected by virus cultures in 23 of the 129 …
Here, we report that infectious virus shedding is detected by virus cultures in 23 of the 129 …
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink, RHN van Schaik… - Clinical …, 2003 - Wiley Online Library
Background The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus have
a narrow therapeutic index and show considerable interindividual variability in their …
a narrow therapeutic index and show considerable interindividual variability in their …
Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report
…, A Åsberg, V Haufroid, DA Hesselink… - Therapeutic drug …, 2019 - journals.lww.com
Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …
Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants
…, RAS Hoek, MM van der Eerden, DA Hesselink… - MedRxiv, 2020 - medrxiv.org
Background Long-term shedding of viral RNA in COVID-19 prevents timely discharge from
the hospital or de-escalation of infection prevention and control practices. Key questions are …
the hospital or de-escalation of infection prevention and control practices. Key questions are …
[HTML][HTML] Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2
DA Hesselink, RM Van Hest, RAA Mathot… - American journal of …, 2005 - Elsevier
In mycophenolate mofetil (MMF)-treated organ transplant recipients, lower mycophenolic
acid (MPA) plasma concentrations have been found in cyclosporine (CsA) compared with …
acid (MPA) plasma concentrations have been found in cyclosporine (CsA) compared with …
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
L Elens, R Bouamar, DA Hesselink, V Haufroid… - Clinical …, 2011 - academic.oup.com
BACKGROUND Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity.
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
DA Hesselink, R Bouamar, L Elens… - Clinical …, 2014 - Springer
The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
L Elens, T Van Gelder, DA Hesselink… - …, 2013 - Future Medicine
Many studies have attempted to explain the interindividual variability observed in drug
metabolism by assessing the impact of SNPs in genes implicated in drug absorption, distribution, …
metabolism by assessing the impact of SNPs in genes implicated in drug absorption, distribution, …
Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management
N Shuker, T van Gelder, DA Hesselink - Transplantation Reviews, 2015 - Elsevier
… links open overlay panel Nauras Shuker a b , Teun van Gelder a b , Dennis A. Hesselink
a … DA Hesselink: Has received lecture and consulting fees, as well as grant support from …
a … DA Hesselink: Has received lecture and consulting fees, as well as grant support from …
Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology
S Bergan, M Brunet, DA Hesselink… - Therapeutic drug …, 2021 - journals.lww.com
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …